Dose 3 Adverse Reactions Similar to Dose 2

October 1, 2021

This morning, the CDC released their Morbidity and Mortality Weekly Report focusing on third doses of the COVID-19 vaccine. The report referenced Pfizer’s Phase 3 clinical trial, which included 306 participants, ages 18-55, who received a booster dose. Doses were administered 5-8 months after completion of a primary series using mRNA vaccines. Adverse reactions were similar to those after the second dose, and “included mild to moderate injection site and systemic reactions” (1).

V-safe was developed by the CDC as a voluntary, self-reporting surveillance system for “local injection site and systemic reactions and health impacts” post-vaccination. From August 12 – September 19, 2021, over 22,000 registrants reported getting a third dose of the COVID-19 vaccine into v-safe. Over 97% reported getting a mRNA vaccine for their primary series, followed by a third dose of the same vaccine. “Voluntary reports to v-safe found no unexpected patterns of adverse reactions after an additional dose of COVID-19 vaccine.” Of those who completed check-ins for all three doses, 79.4% and 74.1% reported local or systemic reactions, respectively, after their third dose. 77.6% and 76.5% reported local or system reactions following their second dose. Moreover, the majority of adverse reactions were mild or moderate in nature.

Safety and efficacy data on mix-and-matching doses from different manufacturers is still limited.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.